Member Info for LordSnooty

please buy a share.

The Dowager Duchess of Ytoons, one's great aunt, was a noted clairvoyant. It is from her, one flatters oneself, that one inherited the gene of second sight, particularly in relation to stock-picking. Sadly, her inner eye was not of sufficient sensitivity - she failed to foresee King George V, stirrups asunder and copious royal bottom athwartships, cantering down The Mall in the winter of 1913, his mount frothing at the bit. Her remains were buried at the church of St Snoot-the-Charitable, in Snooty-under-Water, family seat of the Snootys since before the Conquest. The formidable curmudgeon lies beneath a handsome obelisk, on which is inscribed the legend, 'Trampled by a King but Caressed by Angels'.

if I knew that I would be either clairvoyant or in breach of the law. At a guess, and it is only a guess, I would say, with luck, we will have news of it (but not actual listing) in H1, which leaves about six weeks of so. Also within that time frame, some more clinical news, as per Mr M's interview in February. Plenty to play for, including the fact that noises are beginning to be made in some quarters that AIM is looking cheap.

AIM looks terminal at the moment, particularly for junior pharmas. Roll on news of our US listing. It shouldn't be too far off.

Salutations from Hacienda Snooty, where the serfs are gurning but Snooty's not for turning. It is time you donned your investor's cap and plunged back into XEN again for the long term. A very modest 7p+ is all that is required to become a member of the best club on AIM, which is led of course by the inimitable Snooty - with a little help from Scotty.

moves to Phase II: http://www.proactiveinvestors.co.uk/companies/news/56744/xenetic-biosciences-ms-treatment-moves-to-phase-ii-56744.html# Scott Maguire, Xenetic’s chief executive, said: "The move to dosing MS patients represents an important milestone in this clinical trial. We now have all our platform technologies as represented by their respective products at least in Phase II clinical trials. “We are encouraged with the announcement yesterday on the commencement of the ErepoXen Phase III trial for the treatment of anaemia, where our Russian partners are now making significant progress on our collaboration. We expect to make further announcements on additional clinical candidates in due course."

your 11:51 - you mentioned Russia but you omitted to name our blockbuster, OncoHist. If trial results - first indications of which may come in the next few months - are good, we may go intergalactic.

that "The Snootettes" might be suitable.

and other girls/ladies: welcome and may I sound a note of caution - there is a certain Leeson, late of incarceration in the Orient, who posts the most appalling sexist, golfist and ageist jokes periodically. He is best avoided like the bird flu. Whatever you do, don't allow him to know he is humorous, it will only encourage him.

Ladies, particularly of a certain age, are warmly welcomed by this old peer. I believe Parpaing, an infrequent but valuable visitor to this thread, is also of the distaff persuasion.

I'd say the free float was less than that in practice, judging from the lack of liquidity on days when the MMs are not active. There are a lot of us here who have been in for a few years and clutch our shares to our bosoms with our sweaty hands.

yes, perhaps we'll get some well-earned relief from the Singapore Swindler.

not me, I have a bus pass.

tipping point?

"The move to dosing MS patients represents an important milestone in this clinical trial. We now have all our platform technologies as represented by their respective products at least in Phase II clinical trials. We are encouraged with the announcement yesterday on the commencement of the ErepoXen™ Phase III trial for the treatment of anaemia, where our Russian partners are now making significant progress on our collaboration. We expect to make further announcements on additional clinical candidates in due course."

today we must get an effect, after back to back RNSs? Commencement of Phase II with MyeloXen™, the novel vaccine for Multiple Sclerosis Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological products, vaccines and novel cancer drugs, announces that it has successfully completed Phase I, the initial safety trial for MyeloXen™, and has now treated the first patients in Phase II, the dose escalation part of the trial. MyeloXen™ is the Company's novel treatment for Multiple Sclerosis (MS) and based upon ImuXen™, the Company's patented liposomal technology. Having completed Phase I of the trial on six healthy volunteers without any adverse event, the Company's Russian partner, Pharmsynthez, has now started Phase II of the trial, administering the candidate to 12 patients at escalating dosing levels in order to establish the safe dose level for MyeloXen™. In the final element of the trial the then-established dosing range will be applied for further safety, surrogate efficacy and mode of action analysis.

of two years is misleading, I think: this EPO trial is our most advanced clinically but we have other candidates for which the aim is to license them out after Ph II, thereby deriving both fee and royalty. We are much closer than two years to revenue with those.

as the RNS says, it's our first Ph III trial - a milestone.

Scott Maguire, CEO of Xenetic Biosciences said: "With the commencement of this Phase III trial in Russia, ErepoXen™ is now the most advanced candidate in our portfolio, and with our double-digit royalty agreement with SynBio, we can now see the potential of a recurring revenue stream. We look forward to providing our shareholders with further news on ErepoXen™ as such news develops."

the gouty toe is throbbing like billy-o and has turned a delicate shade of cerise. Snooty predicts an epochal RNS is imminent.